Jonathan Zalevsky
2021
In 2021, Jonathan Zalevsky earned a total compensation of $5M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, which was about the same as previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $471,270 |
|---|---|
| Option Awards | $1,397,498 |
| Salary | $683,000 |
| Stock Awards | $2,391,094 |
| Other | $8,385 |
| Total | $4,951,247 |
Zalevsky received $2.4M in stock awards, accounting for 48% of the total pay in 2021.
Zalevsky also received $471.3K in non-equity incentive plan, $1.4M in option awards, $683K in salary and $8.4K in other compensation.
Rankings
In 2021, Jonathan Zalevsky's compensation ranked 2,657th out of 12,405 executives tracked by ExecPay. In other words, Zalevsky earned more than 78.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,657 out of 12,405 | 79th |
Division Manufacturing | 1,049 out of 5,494 | 81st |
Major group Chemicals And Allied Products | 410 out of 2,369 | 83rd |
Industry group Drugs | 357 out of 2,090 | 83rd |
Industry Pharmaceutical Preparations | 234 out of 1,537 | 85th |
Source: SEC filing on April 29, 2022.
Zalevsky's colleagues
We found four more compensation records of executives who worked with Jonathan Zalevsky at Nektar Therapeutics in 2021.